Guidelines for Cancer Care during the COVID-19 Pandemic in South Korea

Jii Bum Lee1, Minkyu Jung1, June Hyuk Kim2, Bo Hyun Kim3, Yeol Kim4, Young Seok Kim4, Byung Chang Kim5, Jin Kim5, Sung Ho Moon6, Keon-Uk Park6, Meereim Park7, Hyeon Jin Park7, Sung Hoon Sim8, Hong Man Yoon9, Soo Jung Lee10, Eunyoung Lee11, June Young Chun11, Youn Kyung Chung11, So-Youn Jung11, Jinsoo Chung11, Eun Sook Lee11, Hyun Cheol Chung11, Tak Yun12, Sun Young Rha1

1 Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, 2 Song-dang Institute for Cancer Research, Yonsei University College of Medicine, Seoul, 3 Orthopaedic Oncology Clinic, National Cancer Center, Goyang, 4 Center for Liver and Pancreatobiliary Cancer, Research Institute and Hospital, National Cancer Center, Goyang, 5 Division of Cancer Prevention & Early Detection, National Cancer Control Institute, National Cancer Center, Goyang, 6 Department of Radiation Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, 7 Center for Colorectal Cancer, Research Institute and Hospital, National Cancer Center, Goyang, 8 Department of Surgery, Korea University College of Medicine, Seoul, 9 Center for Proton Therapy, Research Institute and Hospital, National Cancer Center, Goyang, 10 Department of Internal Medicine, Keimyung University Dongan Hospital, Daegu, 11 Department of Pediatrics, Center for Pediatric Cancer, Research Institute and Hospital, National Cancer Center, Goyang, 12 Breast Cancer Center, Research Institute and Hospital, National Cancer Center, Goyang, 13 Center for Gastric Cancer, Research Institute and Hospital, National Cancer Center, Goyang, 14 Department of Oncology/Hematology, School of Medicine, Kyungpook National University, Kyungpook National University Chilgok Hospital, Daegu, 15 Center for Hematologic Malignancy, National Cancer Center, Goyang, 16 Department of Internal Medicine, Research Institute and Hospital, National Cancer Center, Goyang, 17 Department of Obstetrics and Gynecology, National Cancer Center, Goyang, 18 Department of Urology, Center for Urologic Cancer, Research Institute and Hospital, National Cancer Center, Goyang, 19 Center for Rare Cancers, Research Institute and Hospital, National Cancer Center, Goyang, Korea

Correspondence: Sun Young Rha
Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 03722, Korea
Tel: 82-2-2228-8053 Fax: 82-2-362-5592 E-mail: rha7655@yuhs.ac

Co-correspondence: Tak Yun
Center for Rare Cancers, Research Institute and Hospital, National Cancer Center, 323 Ilsan-ro, Ilsan-dong-gu, Goyang 10408, Korea
Tel: 82-31-920-1621 Fax: 82-31-920-1520 E-mail: hmotakyun@ncc.re.kr

*Jii Bum Lee, Minkyu Jung, and June Hyuk Kim, contributed equally to this work.

Present address: Division of Hemato-oncology, Wonju Severance Christian Hospital, Yonsei University Wonju College of Medicine, Wonju, Korea

At the end of 2019, the cause of pneumonia outbreaks in Wuhan, China, was identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. In February 2020, the World Health Organization named the disease cause by SARS-CoV-2 as coronavirus disease 2019 (COVID-19). In response to the pandemic, the Korean Cancer Association formed the COVID-19 task force to develop practice guidelines. This special article introduces the clinical practice guidelines for cancer patients which will help oncologists best manage cancer patients during the COVID-19 pandemic.

Key words Cancer care, COVID-19, Guideline, Korea

Introduction

The coronavirus disease 2019 (COVID-19) pandemic is an ongoing global issue [1,2]. In South Korea, the first COVID-19–positive patient was diagnosed on January 20, 2020 [3]. Since then, COVID-19 has caused serious health concerns in the treatment of cancer patients [4-7]. Quarantine protocols have been issued by the South Korean Government, including the Central Disaster and Safety Countermeasures Headquarters [3].

The guideline presented here was developed to help oncologists manage cancer patients who have a high mortality rate. Other countries have developed COVID-19–specific cancer guidelines [7-9]. The difference in situation and management in South Korea prompted the development of guidelines specifically for South Korean oncologists. We hope that these guidelines will provide clinical guidance to cancer care during the ongoing COVID-19 pandemic.

Method

The guideline was first written in Korean in April 2020 by clinical experts who were members of the Korean Cancer Association and the National Cancer Center and include general guidelines for cancer care and specific recommendations for surgery, chemotherapy, radiotherapy, pediatric oncology, cancer screening, and clinical trials. Many of the information provided here were developed from experts’ opinions and experience during the time when COVID-19 pandemic hit Korea in March. The guideline was then translated to English so that the clinicians around the world may have access to this guideline. All authors unanimously agree to the recommendations as outlined in the guideline. In general, the
Guideline for screening, treatment and follow-up for cancer care primarily depends on two factors: (1) the shortages in medical devices or healthcare workers, and (2) whether the patient is positive for COVID-19 (Fig. 1).

**General Guidelines**

1. **Prevention**
   Guidelines for cancer patients may be modified during massive regional or national COVID-19 outbreaks. Clinicians should discuss the benefits and risks of cancer treatment with patients before making treatment decisions. Both healthcare workers and patients should wash their hands and wear masks during face-to-face communication. The clinic and facilities treating patients must be large, open, and well-ventilated. The 2-m social distancing rule should be applied. Patients should be educated about the symptoms of COVID-19.

2. **Treatment**
   COVID-19–positive cancer patients should be treated in the same manner as COVID-19–positive patients without cancer. Stop all cancer treatments such as elective surgery, chemotherapy, and radiotherapy if a cancer patient is diagnosed with COVID-19. Patients should be admitted to hospital since they are at a high risk of severe disease. Cancer treatment may resume once they recover from COVID-19. Patients who have completed their cancer treatment or are under surveillance for recurrence should not postpone routine tests or hospital visits. Postponing follow-up tests and hospital visits should only occur if there are shortages of medical devices or healthcare workers.

3. **Facility**
   Healthcare facilities should establish a diagnostic laboratory in which cancer patients suspected with COVID-19 can be tested rapidly. Establish a network for patient referral and swiftly refer to another hospital when necessary. Prevent delays in patient treatment if there is a COVID-19 outbreak in healthcare facilities. Clinicians are recommended to communicate via telemedicine. Options include telephone-only consultation, virtual check-in, and e-visits.
   Separate triage stations for COVID-19 screening should be established for both outpatient clinics and emergency departments. Patients should be screened if they have the following conditions: (1) symptoms related to COVID-19, (2) a history of recent overseas travel within 14 days, or (3) contact with a COVID-19 patient. Once a patient is tested negative for COVID-19 disease, the patient should be referred to the outpatient clinic or admit to the ward, as appropriate.

**Surgery**

Surgery should not be postponed due to the potential risk of cancer progression. At the discretion of doctors, surgery may be delayed, but the decisions must be based on an individual basis. Emergency operations should never be delayed. Prior to surgery, factors such as the center’s infrastructure to treat COVID-19–positive patients, the status of healthcare workers, and availability of the intensive care units and general wards should be considered. Prior to elective surgery, all patients should be screened for COVID-19.

Clinicians should wear personal protective equipment (PPE) during surgery for febrile patients waiting for COVID-19 test results [10]. The least possible number of staff should be allowed to assist during surgery. The patient should recover in the operation room after surgery. While awaiting the COVID-19 test results, the recovered patient should be send to an isolation ward via a safe route. The patient should be sent to the general ward only after testing negative.

---

**Fig. 1.** Basic algorithm for screening, treatment and follow-up during coronavirus disease 2019 (COVID-19). a)Indications for COVID-19 screening includes one of the following: (1) symptoms related to COVID-19, (2) history of recent overseas travel within 14 days, contact with a COVID-19 patient, b)Delay: Refer to Table 2 for summary of recommendations for cancer screening.
for COVID-19.

The following are necessary equipment for healthcare workers, including surgeons, anesthesiologists, and nurses: PPE including double gloves, N95 face mask, goggles, surgical cap, surgical gown, and shoe covers. For COVID-19 patients or suspected COVID-19 patients, medical staff should wear level D PPE, powered with an air-purifying respirator (PAPR). Alternatives to surgery, such as cancer drugs and radiation treatment, should be considered in the case of large-scale COVID-19 outbreaks that result in a shortage of healthcare workers.

**Chemotherapy**

Chemotherapy should be administered on an individual basis since COVID-19 outbreaks and medical resources can vary regionally. During epidemic breakout of COVID-19, patients with a low risk of COVID-19 should continue routine chemotherapy. During pandemic COVID-19 era, where there is a high risk for COVID-19 leading to a shortage of medical resources and healthcare workers, patients are advised to postpone admission to wards. They are encouraged to be diagnosed and treated in outpatient clinics to prevent COVID-19. Outpatient clinics may be rescheduled. Patients should minimize hospital visits by communicating via telemedicine, preferably by phone or virtually, rather than having face-to-face interaction.

Clinicians are advised to implement treatment strategies with fewer hospital visits. Clinicians may change the route of chemotherapy (hormonal treatment) from intravenous to oral and treat in outpatient clinics. If possible, use chemotherapy with longer treatment cycles to avoid frequent hospital visits.

Cancer patients receiving adjuvant chemotherapy should not delay treatment except during a shortage of medical resources, in which case the patients should be referred to other hospitals. The clinicians should discuss the benefits and risks of omitting or delaying treatment, including the possibility of recurrence to the patients.

Patients with advanced or recurrent solid tumors requiring palliative chemotherapy should continue treatment. During a shortage of medical resources, chemotherapy may be postponed only if the primary physician believes that the disease progression is slow and the cancer-related symptoms are minimal. However, palliative chemotherapy should not be delayed if the patient is experiencing symptoms or rapid progression. Implement ways to minimize emergency department visits related to chemotherapeutic side effects.

In patients with febrile neutropenia after chemotherapy, clinicians should exercise caution because it is difficult to distinguish COVID-19 from other viral infections. Clinicians are advised to use granulocyte colony-stimulating factor. Dose reduction or delay future chemotherapy should be considered in the next treatment cycle. COVID-19 must be screened for asymptomatic patients who need admission to ward. However, it is not mandatory for asymptomatic patients receiving chemotherapy in the outpatient clinic.

**Radiotherapy**

Generally, patients with de novo tumors requiring radiotherapy should not mandatorily delay radiation treatment. However, radiotherapy may be withheld and substituted with other treatment if the patient is asymptomatic or in poor general condition. During a shortage of medical resources, radiation may be delayed at the discretion of the radiation oncologist. With the exception of emergency and life-threatening conditions such as spinal cord compression, cauda equina syndrome, increased intracranial pressure, superior vena cava syndrome, obstruction of airways, hemoptysis, and tumor bleeding, all other elective radiotherapy may be delayed. For hypofractionated radiotherapy, the dosage of radiation maybe increased and the frequency of treatment decreased.

For patients who are tested positive for COVID-19, radiation treatment may be withheld unless they require the immediate interventions due to emergency and life-threatening conditions. Treatment may be resumed once the patient recovers from COVID-19. Radiologists may consider increasing the total dose of radiation after the unexpected “treat-

**Table 1. General guidelines for cancer screening**

| Criteria                     | Recommendations                                                                 |
|------------------------------|----------------------------------------------------------------------------------|
| For patients                 | Patients are instructed to take off their face mask only when necessary (ex: esophagogastroduodenoscopy). Otherwise, patients must wear their face mask at all times. |
|                              | Apply the 2-m social distancing rule in waiting areas.                           |
|                              | The outpatient clinic should be limited to one patient at a time during a procedure. |
| For healthcare workers       | Wash hands before and after contact with the patient and surrounding areas.      |
|                              | If possible, consider communicating results over the phone.                      |
After completion of radiotherapy, follow-up visits may be delayed or minimized at the discretion of radiation oncologists. In patients with stable condition who do not have any side effects from radiation treatment, less stringent follow-up visits are recommended with a follow-up of 3-month period.

Pediatric Oncology

Currently, there are no guidelines for treatment of pediatric COVID-19 patients. Generally, pediatric cancer patients higher risk for COVID-19 complications than healthy adults [11]. In infants, children, and adolescents, the symptoms of COVID-19 appear as respiratory symptoms, such as fever, cough, and dyspnea, and non-respiratory symptoms, such as vomiting and diarrhea.

Chemotherapy in pediatric oncology patients should not be delayed. Patients who received chemotherapy or surgery within a month of COVID-19 are likely to develop more severe infection. Therefore, patients with symptoms such as fever and cough should be treated promptly. Minimize hospital visits by delaying outpatient clinic appointments or substituting with telephone-only visits for patients who have completed chemotherapy. Maintain regular follow-up visits. Consider switching from intravenous drugs to oral drugs, if possible.

Table 2. Summary of recommendations for cancer screening

| Cancer              | Gastric cancer | Colon cancer | HCC       | Cervical cancer | Lung cancer | Breast cancer |
|---------------------|----------------|--------------|-----------|----------------|-------------|---------------|
| Diagnostic modality| Endoscopy      | Endoscopy    | USG, AFP  | Pap smear       | LDCT        | Mammography   |
| Risk stratification| -              | -            | Prioritize screening for high risk patients<sup>a</sup> | -            | -           | -             |
| Preventative measures for healthcare workers | PPE<sup>b</sup> | PPE<sup>c</sup> | -         | -              | -          | -             |
| Sanitation protocol | Required<sup>d</sup> | Required<sup>d</sup> | -        | -              | -          | -             |
| For COVID-19–positive asymptomatic patients | Enhanced PPE (level D, powered with an PAPR) | Enhanced PPE (level D, powered with an PAPR) | - | - | - | - |

AFP, α-fetoprotein; COVID-19, coronavirus disease 2019; HCC, hepatocellular carcinoma; LDCT, low-dose computed tomography; PAPR, air-purifying respirator; PPE, personal protective equipment; USG, ultrasonography. <sup>a</sup>High risk patients include patients with elevated AFP levels, liver cirrhosis, or chronic hepatitis B. <sup>b</sup>PPE includes gloves, face mask, plastic barrier gown and goggles/face shields. Enhanced PPE includes level D, powered with an PAPR. <sup>c</sup>Refer to Table 3 for sanitation protocol.

Table 3. Specific recommendations for screening with endoscopy

| Criteria                  | Recommendations                                                                 |
|---------------------------|---------------------------------------------------------------------------------|
| Sanitization protocol     | Follow the protocols as outlined by the Korean Society of Gastrointestinal Endoscopy [13]. |
|                           | Use disinfectant wipes to clean the bed after each endoscopic procedure.        |
|                           | Disinfectant containing bleach (1:40, sodium hypochlorite 25 mL: water 1 L, 1,000 ppm) must be used to clean the floor. |
|                           | Use disinfectant wipes such as Rely+On Virkon Micro Tissue or ED wipes.         |
|                           | For a suspected COVID-19 patient, disinfect all areas that had contact with the patient including the equipment and floors. Rub with disinfectant at least three times. |
| Facility cleaning         | Use ceiling-mounted air conditioners with fan coils to ventilate.               |
|                           | Place the air vents in the area for disinfecting and cleaning the endoscopes.  |
|                           | Open the doors and windows in the waiting area twice a day, in the morning and afternoon. |
|                           | Use checklists for cleaning and clean facility twice a day, in the morning and afternoon. |

COVID-19, coronavirus disease 2019.
### Table 4. Summary of cancer care during COVID-19

| Criteria                  | Recommendations                                                                                                                                                                                                 |
|---------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| General guidelines        | Both healthcare workers and patients should wash their hands and wear masks during face-to-face communication. The 2-m social distancing rule should be applied. COVID-19–positive cancer patients should be treated in the same manner as COVID-19–positive patients without cancer. Stop all cancer treatments such as elective surgery, chemotherapy, and radiotherapy if a cancer patient is diagnosed with COVID-19. Postponing follow-up tests and hospital visits should only occur if there are shortages of medical devices or healthcare workers. Separate triage stations for COVID-19 screening should be established for both outpatient clinics and emergency departments. Patients should be screened if they have the following conditions: (1) symptoms related to COVID-19, (2) a history of recent overseas travel, or (3) contact with a COVID-19 patient. |
| Surgery                   | Surgery should not be postponed due to the potential risk of cancer progression. Prior to elective surgery, all patients should be screened for COVID-19. Clinicians should wear personal protective equipment (PPE) which includes double gloves, N95 face mask, goggles, surgical cap, surgical gown, and shoe covers. For COVID-19 patients or suspected COVID-19 patients, medical staff should wear Level D PPE, powered with an air-purifying respirator (PAPR). Alternatives to surgery, such as cancer drugs and radiation treatment, should be considered in the case of large-scale COVID-19 outbreaks that result in a shortage of healthcare workers. |
| Chemotherapy              | Clinicians are advised to implement treatment strategies with fewer hospital visits. For patients treated in adjuvant or palliative setting, we advise that the treatments should not be delayed. Use granulocyte colony-stimulating factor in patients with febrile neutropenia after chemotherapy, and consider dose reduction or delay in subsequent chemotherapy. COVID-19 must be screened for asymptomatic patients who need admission to ward. |
| Radiotherapy              | Patients with de novo tumors requiring radiotherapy should not delay radiation treatment. With the exception of emergency and life-threatening conditions such as spinal cord compression, cauda equina syndrome, increased intracranial pressure, superior vena cava syndrome, obstruction of airways, hemoptysis, and tumor bleeding, all other elective radiotherapy may be delayed during a shortage of medical resources. During a shortage in medical resources, the dosage of radiation maybe increased and the frequency of treatment for hypofractionated radiotherapy. Follow-up visits may be delayed after a multi-disciplinary approach. |
| Pediatric oncology        | Pediatric cancer patients are immunocompromised, more susceptible to viral infections including COVID-19, and have a higher COVID-19 mortality rate. Both donor and recipient are screened for COVID-19 should be screened prior to stem cell transplantation. |
| Cancer screening          | Cancer screening should not be delayed in healthy patients. Asymptomatic patients who are unlikely to have COVID-19 may proceed with cancer screening without COVID-19 results. With the exception of screening with endoscopy, all cancer screening should be delayed in COVID-19–positive patients until they are tested negative. Healthcare workers must use PPE during the procedure and follow sanitation protocols during endoscopic procedures. |
| Clinical trial            | The trial sponsors and clinical trial centers, including the Institutional Review Board (IRB) members and the principal investigators, should adhere to the protocol outlined by the Ministry of Food and Drug Safety. Ensure the safety of patients and staff by taking precautionary measures during the storage, shipment, and delivery of biological samples. |

COVID-19, coronavirus disease 2019.
lines recommend that both donor and recipient are screened for COVID-19 [12]. Prior to stem cell transplantation, optimize blood storage to prevent a lack of blood supply during transfusions.

All treatments, including non-elective surgery, chemotherapy, and radiotherapy should be withheld in COVID-19–positive pediatric patients, and COVID-19 should be treated immediately. Admit the patients to hospitals since they are at a high risk of serious disease. Patients should be rigorously monitored even after treatment, since they are immunocompromised and can spread COVID-19 even if they are asymptomatic. Cancer-related treatments may resume once they recover from COVID-19.

**Cancer Screening**

The guidelines for cancer screening are outlined in Table 1. In general, cancer screening should not be delayed in healthy patients. Asymptomatic patients who are unlikely to have COVID-19 may proceed with cancer screening without COVID-19 results. Screening methods such as Pap smear, mammography, and low-dose computed tomography for cervical cancer, breast cancer, and lung cancer respectively, may be postponed if there is a shortage of medical resources. With the exception of screening with endoscopy, all cancer screening should be delayed in COVID-19–positive patients until they are tested negative (Table 2).

For gastric and colon cancer screening, check if the patients have fever or respiratory symptoms and screen for COVID-19. Healthcare workers must use PPE during the procedure and follow sanitation protocols during endoscopic procedures. For COVID-19–positive asymptomatic patients, proceed with the endoscopy in a setting of enhanced PPE (level D, powered with an PAPR). Follow the protocols for sanitation and facility cleaning as recommended in Table 3. For patients screening for hepatocellular carcinoma, risk factors should be stratified. Patients with low risk may postpone screening. During a shortage of medical resources, prioritize screening patients who have elevated α-fetoprotein levels, liver cirrhosis, and chronic hepatitis B. Encourage patients who are current smokers and are at high risk of both lung cancer and COVID-19, to stop smoking.

**Clinical Trials**

Patient safety is the foremost priority during clinical trials. The principal investigator, sub-investigator, and clinical research coordinator must follow the general guidelines for COVID-19 prevention. The trial sponsors and clinical trial centers, including the Institutional Review Board (IRB) members and the principal investigators, should adhere to the protocol as outlined by the Ministry of Food and Drug. The investigators should consult sponsors about the possibility of protocol deviations during the COVID-19 pandemic. Clinicians should enroll and treat the subject as outlined in the clinical trial protocol. Assess and ensure the safe shipment of investigational products. Ensure the safety of patients and staff by taking precautionary measures during the storage, shipment, and delivery of biological samples. One method is to sanitize the external packages received.

**Conclusion**

The summary of general guidelines, surgery, chemotherapy, radiotherapy, pediatric oncology, cancer screening, and clinical trial for cancer patients during the COVID-19 pandemic is outlined in Table 4. Lastly, individualized treatment strategies and discretion of clinicians are needed to adjust to the challenges faced with maintaining cancer care in the COVID-19 era.

**Author Contributions**

Conceived and designed the analysis: Jung M, Kim JH, Kim BH, Kim Y, Kim YS, Kim BC, Kim J, Moon SH, Park KU, Park M, Park HJ, Sim SH, Yoon HM, Lee SJ, Lee E, Chun JY, Chung YK, Jung SY, Chung J, Lee ES, Chung HC, Yun T, Rha SY.

Collected the data: Kim JH, Kim BH, Kim Y, Kim YS, Kim BC, Kim J, Moon SH, Park KU, Park M, Park HJ, Sim SH, Yoon HM, Lee SJ, Lee E, Chun JY, Chung YK, Jung SY, Chung J, Lee ES, Chung HC, Yun T, Rha SY.

Contributed data or analysis tools: Kim JH, Kim BH, Kim Y, Kim YS, Kim BC, Kim J, Moon SH, Park KU, Park M, Park HJ, Sim SH, Yoon HM, Lee SJ, Lee E, Chun JY, Chung YK, Jung SY, Chung J, Lee ES, Chung HC, Yun T, Rha SY.

Wrote the paper: Lee JB, Jung M, Kim JH.

**Conflicts of Interest**

Conflict of interest relevant to this article was not reported.

**Acknowledgments**

We would like to thank all the board members from the Korean Cancer Association and the Office of Public Relations and Collaboration at the National Cancer Center, South Korea, for supporting the development of these COVID-19 clinical practice guidelines for cancer care.
References

1. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-33.
2. Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395:565-74.
3. Dighe A, Cattarino L, Cuomo-Dannenburg G, Skarp J, Imai N, Bhatia S, et al. Response to COVID-19 in South Korea and implications for lifting stringent interventions. BMC Med. 2020;18:321.
4. Jazieh AR, Akbulut H, Curigliano G, Rogado A, Alsharm AA, Razis ED, et al. Impact of the COVID-19 pandemic on cancer care: a global collaborative study. JCO Glob Oncol. 2020;6:1428-38.
5. Lambertini M, Toss A, Passaro A, Criscitiello C, Cremolini C, Cardone C, et al. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’ perspective. ESMO Open. 2020;5:e000759.
6. de Joode K, Dumoulin DW, Engelen V, Bloemendal HJ, Verheij M, van Laarhoven HW, et al. Impact of the coronavirus disease 2019 pandemic on cancer treatment: the patients’ perspective. Eur J Cancer. 2020;136:132-9.
7. Neal RD, Neklyudov L, Wheatstone P, Koczwara B. Cancer care during and after the pandemic. BMJ. 2020;370:m2622.
8. Burki TK. Cancer guidelines during the COVID-19 pandemic. Lancet Oncol. 2020;21:629-30.
9. Ueda M, Martins R, Hendrie PC, McDonnell T, Crews JR, Wong TL, et al. Managing cancer care during the COVID-19 pandemic: agility and collaboration toward a common goal. J Natl Compr Canc Netw. 2020;18:366-9.
10. Rhee SW. Management of used personal protective equipment and wastes related to COVID-19 in South Korea. Waste Manag Res. 2020;38:820-4.
11. Saab R, Obeid A, Gachi F, Boudiaf H, Sargsyan L, Al-Saad K, et al. Impact of the coronavirus disease 2019 (COVID-19) pandemic on pediatric oncology care in the Middle East, North Africa, and West Asia region: a report from the Pediatric Oncology East and Mediterranean (POEM) group. Cancer. 2020;126:4235-45.
12. Ljungman P, Mikulska M, de la Camara R, Basak GW, Chabannon C, Corbiacioglou S, et al. The challenge of COVID-19 and hematopoietic cell transplantation; EBMT recommendations for management of hematopoietic cell transplant recipients, their donors, and patients undergoing CAR T-cell therapy. Bone Marrow Transplant. 2020;55:2071-6.
13. Son BK, Kim BW, Kim WH, Myung DS, Cho YS, Jang BL, et al. Korean Society of Gastrointestinal Endoscopy guidelines for endoscope reprocessing. Clin Endosc. 2017;50:143-7.